New Pharmacovigilance Legislation adopted
Following the adoption by the Council and the European Parliament, the new legislation on pharmacovigilance was published on 31 December 2010 in the Official Journal of the EU .
The new legislation, a Regulation and a Directive, will become applicable in July 2012.
This legislation is the outcome of the legal proposals on pharmacovigilance that the Commission put forward in December 2008. The new legislation will strengthen and rationalise the current system for monitoring the safety of medicines on the European market. The strengthened legislation on Pharmacovigilance will improve patient safety and public health through better prevention, detection and assessment of adverse reactions to medicines. It will also allow patients to report adverse drug reactions directly to the competent authorities. Additionally, reporting of adverse reactions will be broadened to cover, for example, medication errors and overdose.
Related GMP News
17.09.2025When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
17.09.2025Dealing with Systems without Audit Trail Functionality
17.09.2025Why is RCA (Root Cause Analysis) so important?
10.09.2025The Use of Hoses in Pharmaceutical Production
10.09.2025Revision of EU-GMP Chapter 1 planned with Consultation Phase
10.09.2025Audit Trail Review by the QP / Dealing with a Lack of Justification